NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Acquired resistance limits EGFR tyrosine kinase inhibitor (TKI) efficacy in EGFR-mutated non-small cell lung cancer (NSCLC), often due to the T790M mutation.
• Selective EGFR-T790M inhibitors represent a promising therapeutic strategy for overcoming this resistance.

Purpose of the Study:

• To evaluate the efficacy of the novel irreversible EGFR-TKI CNX-2006 against EGFR-mutated NSCLC models.
• To investigate the mechanisms of acquired resistance to CNX-2006 and identify potential therapeutic targets.

Main Methods:

• Utilized isogenic cell pairs for integrated genetic and functional analyses.
• Assessed the activity of CNX-2006 in vitro and in vivo NSCLC models.
• Investigated the role of NF-κB1 in acquired resistance and its potential as a therapeutic target.

Main Results:

• CNX-2006 demonstrated activity against mutant EGFR NSCLC models with minimal effect on wild-type EGFR.
• NF-κB1 was identified as a crucial factor in acquired resistance to CNX-2006.
• NF-κB activation can compensate for inhibited EGFR signaling in T790M-mutated NSCLC.
• Inhibition of NF-κB, genetically or pharmacologically, reduced the viability of resistant cells.

Conclusions:

• NF-κB1 plays a critical role in acquired resistance to novel EGFR-TKIs in NSCLC.
• Targeting the NF-κB pathway is a promising therapeutic strategy for patients with acquired resistance to EGFR-TKIs.
• Combined inhibition of EGFR and NF-κB may improve treatment outcomes in resistant NSCLC.